Press Room

Press Clipping / Nov 16, 2018

Employee focus on ethical issues keeps firms on a righteous path

Irish Examiner, November 16, 2018

This year, a further seven companies were recertified to the standard: Boots Retail, CRH, Deloitte, ESB, Gas Networks Ireland, Intel and KBC Bank Ireland.

In all, 33 companies have now achieved the BWR mark, which is hosted by Business in the Community Ireland (BITCI), which assesses applicant companies’ sustainability and corporate social responsibility commitments.

Significantly, this year’s event also saw 43 companies pledge to cut their carbon emissions between now and 2030. The signatories are in retail, manufacturing, agri-food, professional services, banks, transport and ICT.

It is becoming increasingly important for Irish companies to measure and prove their commitments to sustainability, the environment and engagement with employees and local communities. And nudging those commitments on are their existing and prospective new employees, who are becoming increasingly insistent on working in a caring workplace.

“We look at companies’ activities across the board, across their various management practices,” said BITCI’s CEO, Tomás Sercovich.

The companies speak very highly of the mark, and that is because we are very thorough about the audit process. We have 22 auditors who conduct best-in-class audits. Companies find it useful to have a third party come in to observe their policies in practice

“The truth is that companies are also very good at using this mark as a way of differentiating themselves in an increasingly complicated employment market. I know there are people working in life sciences who changing jobs, some just crossing the road to take work with a competitor.” In many cases, the employees are citing ethical grounds when changing jobs. Mr Sercovich said many new graduates are now asking companies policy questions about plastic, recycling and carbon footprint at interviews.

In the case of Cork Harbour industries, would-be employees are asking about any impacts on the harbour. In retail, companies are also becoming more attuned to the ethical antennae of their employees. One Dutch supermarket recently introduced a plastic-free aisle.

“Millennials in particular are looking to work with companies who have deep commitments across a range of issues,” Mr Sercovich said. “They’re digging deep with their questions. They won’t accept a box-ticking exercise, they want companies with real values integrated into their business models and their everyday activities.” This is where BITCI’s support is so important to companies. Going for the BWR mark is not without its risks. Attaining the mark is really demanding, so there is a very real risk of being embarrassed by falling short. Several recipients said they were relieved as well as delighted.

“We’re extremely proud to have achieved the Business Working Responsibly mark,” said Maarten Schuurman, managing director, Heineken Ireland. “It’s wonderful to see the emphasis we place on sustainability and responsibility across all aspects of our business recognised and benchmarked independently.

“The mark serves as a clear signal to our stakeholders and our customers and consumers that we are listening; that we know sustainability matters to them as much as it does to us; and that we are working every day to make Heineken Ireland a truly green brewer.” Kathryn D’Arcy, Heineken’s director of corporate affairs, added: “Our commitment to sustainability and the environment is a long journey. We need to make decisions today that will have a positive impact on the world for the people who are coming behind us.

“Heineken has built up a proud heritage over 160 years. We’re producers of premium beers and ciders. Using only quality sustainable ingredients is at the heart of what we do. The Business Working Responsibly mark is a useful part of our journey. We want our heritage and commitments to be around for another 160 years.”

Meanwhile, Hovione in Ringaskiddy is another of this year’s four new companies to achieve the Business Working Responsibly mark. It is also one of those to have signed up to BITCI’s dedicated pledge to significantly reduce their carbon emissions.

“The award fits in well with our commitment to operating sustainably,” said Paul Downing, general manager of Hovione. “We have done a lot of work in managing our carbon footprint.

Achieving the Business Working Responsibly mark is important to us, and we will be celebrating the award with our staff and the on-site team dedicated to managing this for us. The mark is also important in terms of attracting and retaining talented employees

Dr. Downing said it is increasingly a feature for job candidates to ask about companies’ commitments to the environment, their employees and their local community. Membership of BITCI is one useful measure for demonstrating Hovione’s commitments.

“People joining the company frequently ask questions about our corporate social responsibility programme,” said Mr Downing. “The Business Working Responsibly mark is a very useful measure of our environmental and community commitments.”

Hovione is also the first chemical or pharmaceutical company to become B Corp certified. B Corp is a global community of companies committed to collectively solving social and environmental problems.

 

Read the entire article

 

 

Also in the Press Room

See All

The investment includes both continuous and batch tableting capabilities, as well as connect spray drying with tablet production at its East Windsor campus. Hovione, a Portugal-based contract development and manufacturing organization (CDMO), plans to install a continuous tableting line at its East Windsor, New Jersey campus, adding drug product manufacturing capacity and an integrated pathway from amorphous solid dispersion production through commercial tablet manufacturing. The $35 million investment will bring the first ConsiGma CDC Flex system to Hovione’s recently opened 89 Twin Rivers facility. The line is expected to be commissioned in late 2027 and will support both continuous and batch operation at throughputs ranging from 1 to 200 kilograms per hour, according to the announcement. The system will allow customers to use the same equipment for development, clinical, and commercial production, with formulation development possible using as little as 1.5 kilograms of material. Hovione said the line will also be equipped for containment to 1 microgram per cubic meter to support the handling of highly potent compounds. The new capability will also connect Hovione’s spray-drying operations with tablet manufacturing at the East Windsor campus. The company recently opened a 31,000-square-foot facility at the campus with two commercial-scale spray dryers for manufacturing amorphous solid dispersions (ASDs), completing a $100 million investment in its New Jersey operations. Hovione said the integrated setup will allow customers to move from formulation and particle engineering through tablet production under one quality system, reducing technology transfer requirements and eliminating traditional scale-up between development and commercial production. The ConsiGma CDC Flex platform was jointly developed with GEA as part of a collaboration that began in 2022, the company said. The system incorporates automated process controls and process analytical technology for real-time monitoring during production. Hovione already operates continuous tableting technology at its Loures, Portugal site. In August, the company completed a more than €40 million expansion of its tablet development and manufacturing center there, adding a second commercial-scale tableting line and increasing the center's manufacturing area by 25%. The East Windsor installation will extend Hovione’s continuous tableting capabilities to the U.S. and expand its integrated drug development and manufacturing services for oral solid dosage products. Read the full article at Pharma Manufacturing 

Press Clipping

Hovione to add $35M continuous tableting line at New Jersey site

Oct 06, 2026

Hovione, a globally integrated pharmaceutical contract development and manufacturing organisation (CDMO), will commission the world’s first ConsiGma CDC flex – a next generation continuous tableting line – at its East Windsor, New Jersey (USA) campus in late 2027. The line will be installed at 89 Twin Rivers, Hovione’s recently opened facility, expanding the company’s drug product capabilities and strengthening its integrated pharmaceutical development and manufacturing hub in the US. CDC ConsiGma flex system The project represents an investment of $35 million. Once installed it will create an integrated pathway from amorphous solid dispersion manufacturing via spray drying through commercial tablet production. The new flex will operate in continuous or batch modes across a very broad throughput range (from one to 200 kg/h). Customers will be able to develop a formulation using small quantities of material, down to 1.5 kg, and then run from very small clinical batches to large commercial batches using the same equipment. This is enabled by specialised design within the flex to effectively switch between continuous blenders of various sizes. Additionally, the line will be installed for containment to 1 µg/m³, supporting highly potent compounds. Continuous tableting is reshaping manufacturing of oral solid dosage medicines and is well suited to programmes in which speed, supply resilience and efficient use of high-value active pharmaceutical ingredients (APIs) are priorities. Inline process analytical technology (PAT) and automated controls also provide real-time quality monitoring. In parallel, the 2022 adoption of ICH Q13 regulatory framework, guidance specifically for continuous manufacturing of drug substances and drug products, provides harmonisation across the US, Europe and Japan. As of 2024, 17 products manufactured under the international guidance have been approved by the US Food and Drug Administration (FDA) alone.  Developed jointly with GEA, the ConsiGma CDC flex platform also incorporates SimpleCT, a suite of automation and control tools with smart interfaces that supports a single process from development to commercial supply. Designed for versatility and ease of use, these innovative developments simplify operation, improve efficiency and containment, and enhance operator safety. Read the full article at Pharma Press UK 

Press Clipping

Hovione to commission world’s first ConsiGma CDC flex, bringing next-generation continuous tableting to the US

Oct 06, 2026

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization.   Read the full article at PharmTech.com  

Press Clipping

Can Continuous Tableting End Scale-Up for Complex Oral Drugs?

Oct 05, 2026